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1. Introduction 
Hypertension after kidney transplantation is an important factor for both graft and patient 
survival. Arterial hypertension in renal graft recipient is defined as the blood pressure 
higher than 140/90 mmHg. According to the recent guidelines, the target blood pressure 
should be less than 138/85 mmHg.[1] 
Blood pressure in renal graft recipient is one of the most important factors with negative 
impact on the survival of kidney graft. Correlation between blood pressure and long-term 
graft survival is extremely significant.[2] The introduction of the calcineurin inhibitors into 
the post transplant immunosupressive protocols has increased the prevalence of 
hypertension after kidney transplantation.  
2. Epidemiology 
Cardiovascular disease is the most frequent cause of morbidity and mortality after renal 
transplantation and remains a significant barrier to improve long-term outcomes.Although 
transplantation improves life expectancy compared with dialysis, survival remains well 
below general population estimates. Approximately 50% of patients die with a functioning 
transplant, with approximately 50% of these deaths from cardiovascular disease or stroke.[3] 
Cardiovascular death rates underestimate the full impact of this disease process given the 
large number of nonfatal events, including acute myocardial infarction, cardiac arrhythmias, 
heart failure, and stroke, that affect quality of life. 
Transplant recipients are at an increased cardiovascular risk secondary to a variety of 
modifiable and non modifiable factors, which should be early recognized, continuously 
monitored and, if possible, thoroughly treated. Blood pressure (BP) represents a non-
immunological risk factor that should be readily amenable to intervention. Nevertheless, 
control rates are disturbingly poor and arterial hypertension is observed in the majority of 
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this patient population. The blood pressure frequently rises after kidney transplantation, as 
hypertension develops in up to 60 to 80 or more percent of renal allograft recipients.[4-6] 
Also, it is not unusual have poorly controlled blood pressure among kidney transplant 
recipients. In a single center study, for example, only 5 percent of kidney transplant patients 
were normotensive as defined by blood pressures less than 130/80 mmHg as measured by 
ambulatory blood pressure monitoring. [6] 
3. Pathophysiology and causes 
There are different factors that cause the appearance of hypertension: renal artery stenosis, 
immunosuppressive medications especially calcineurin inhibitors (cyclosporine and 
tacrolimus), corticosteroids, graft dysfunction, chronic allograft nephropathy (CAN), 
recurrent or “de novo” disease as well as genetic predisposition of donor and recipent. 
Most transplant recipients have suffered from long-lasting chronic kidney disease (CKD) 
and have been treated with hemodialysis or peritoneal dialysis for a certain period. These 
patients exhibit structural and functional vascular abnormalities, as reflected by the high 
prevalence of elevated systolic BP and increased pulse pressure. BP in these patients is 
usually difficult to manage and often volume or salt-dependent. Older age, diabetes mellitus 
and a high cardiovascular disease burden are common comorbidities. 
An association between hypertension and deterioration of renal function does not prove a 
causal relationship. Hypertension after transplantation might simply be the result of a 
deterioration in graft function rather than vice versa. Retrospective studies demonstrating 
an association between hypertension after transplantation and graft survival, cannot 
differentiate between cause and effect.[2, 7] 
The first evidence that hypertension per se may lead to graft damage was the observation 
that not only hypertension after transplantation, but also hypertension before 
transplantation is associated with later CAN. Hypertension before transplantation increased 
the risk for later CAN by a factor of 3.4, the magnitude which was only surpassed by late 
(>60 days after transplantation) acute rejection episodes, which increased the risk for CAN 
by 5.5.[8] 
Studies in animals support the concept of hypertension-induced graft damage. In two 
different hypertensive animal models (clipped native kidney plus allograft [9] or 
transplantation into spontaneous hypertensive rats [10]) it was shown that hypertension 
may aggravate graft damage. 
Another elegantly designed study on rat allograft models explored the mechanisms by 
which hypertension contribute to CAN. [11] Rats were either left normotensive or were 
made hypertensive by treatment with deoxycorticosterone acetate (DOCA) and salt. 
Proteinuria was measured monthly, grafts were harvested at 3 and 6 months for semi-
quantitative real time PCR for smooth muscle cell-growth factors PDGF and TGF-β and for 
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immunohistology. Systolic blood pressure was markedly elevated in rats receiving 
DOCA/salt. Proteinuria was elevated in untreated allografts compared to isografts and was 
further raised in hypertensive animals. Expression of mRNA for PDGF was higher in 
allografts than in isografts and was highest in hypertensive animals. Similarly, significantly 
more tubular cells expressing the ‘proliferating cell nuclear antigen’ as well as more 
extracellular matrix deposition were observed in hypertensive animals compared to 
untreated allografts. In addition, increased expression of MHC I and II was observed in 
hypertensive animals by both immunohistology and RT–PCR. Thus, hypertension may 
influence the immunogenicity of the graft. 
These data indicate that hypertension of the recipient acts together with alloantigen-
dependent factors on the expression of growth factors in the graft thought to be responsible 
for the morphological changes observed in CAN, particularly the vascular changes with 
proliferation of smooth muscle cells leading to neointimal proliferation.[12] Hypertension 
may initiate inflammatory pathways or act synergistically with alloantigen-dependent 
factors on graft injury. 
3.1. Role of immunosupressive drugs in development of hypertension 
Immunosuppressive drugs have an important role in the development of hypertension in 
renal transplant patient. The majority of patients that use cyclosporine do have hypertension 
that usually normalizes after discontinuation of the incriminated immunosuppressant. 
Patients that have been using cyclosporine for more than a year develop a need for 
antihypertensive drug(s) in 20-100% of cases.[13] Most often, it is only a slightly elevated 
blood pressure that can be successfully controlled with antihypertensives. However, 
children can develop a serious hypertension combined with neurological complications 
including “grand mal” convulsions after transplantation, due to high doses of cyclosporine 
and vasoconstriction.[14] 
Before cyclosporine A was introduced in 1983, 50% of the patients with transplanted kidney 
developed hypertension. After calcineurin inhibitors (cyclosporine and tacrolimus) were 
introduced the incidence of hypertension surged up to 70-90%.[15] The usage of 
cyclosporine and tacrolimus is associated with reduced production of nitrogen oxide and 
increased production of endothelin as well as reduced endothel function. These factors lead 
to the reduction of vasodilatation on one hand and the increase of vasoconstriction on the 
other hand, which consequently lead to hypertension. Cyclosporine nephrotoxicity and 
resulting chronic nephrosclerosis, thrombotic microangiopathy are probably caused by 
increased sympathic activity, and reduced renal prostaglandin synthesis as well as 
stimulation of renin-angiotensin-aldosterone (RAAS) systems. [16] 
Many authors agree that the influence of cyclosporine and tacrolimus on incidence of post-
transplant hypertension is evident. However, the probability for developing a post-
transplant hypertension in patients on tacrolimus, is at least 5% lower than in those on 
cyclosporine therapy. However, the others argue that tacrolimus in higher doses is no 
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different from cyclosporine in terms of risk for development of post-transplant 
hypertension. [17] 
Calcineurin inhibitor (CNI) free immunosuppression has, therefore, been advocated due to 
the favorable cardio-metabolic profile. In patients receiving belatacept-based 
immunosuppressive regimens and the mammalian target of Rapamycin (mTOR) inhibitor 
sirolimus both systolic and diastolic blood pressure were lower compared with patients on 
CNI.[18] 
Cyclosporine-induced hypertension was more of a problem in the early years of its 
widespread use in which target levels and treatment doses were significantly higher than 
today. However, in the modern era of individualized immunosuppression and after the 
publication of the results of the Efficacy Limiting Toxicity Elimination (ELITE)-Symphony 
study [19, 20] CNI minimization but not complete avoidance is being supported as the best 
available treatment strategy. Furthermore, findings that chronic humoral rejection may be a 
major cause of chronic allograft changes and late allograft failure annihilate the common 
perception that CNIs are responsible for interstitial fibrosis and tubular atrophy.[21] Thus, 
CNI-free combinations are reserved only for selected patients and CNIs are considered to be 
essential for the management of renal transplant recipients. 
Corticosteroids as integral part of basic immunosuppressive protocols also have an 
important role as one of the possible causes for post-transplant hypertension. Volume 
retention caused by corticosteroids partially explains its hypertensive properties. It is 
proven that the decrease of corticosteroid dose leads to a significant decrease of post-
transplant hypertension, as well as reduced body mass index that is considered to be one of 
the causes for the appearance of post-transplant hypertension.[22] Corticosteroids can 
deteriorate hypertension with their hemodynamic and hormone properties reflecting 
through salt and water retention. The usual steroid dose, 10 mg per day or less, however, 
does not present a significant cause of hypertension.[23] 
The well known side-effects of corticosteroids have motivated interest in steroid-free 
immunosuppression for as long as these agents are available. Steroid withdrawal is possible 
in many transplant recipients with comparable patient and graft survival.[24, 25] 
Unfortunately, rejection rates are higher and allograft fibrosis seems to be more common. 
Still, there may be a advantageous trade-off in terms of reduction of cardiovascular risk 
factors including hypertension, diabetes and dyslipidaemia.[26] Corticosteroids may 
contribute more to hypertension early after transplantation or during pulse rejection therapy 
due to higher doses administered.[27] Glucocorticosteroid-mediated hypertension seems to 
result from increased peripheral vascular resistance through direct action on the vascular 
smooth muscle cells and not through the activation of the mineralcorticoid receptor.[28] 
3.2. Role of allograft nephropathy in development of hypertension 
It is accepted for a fact that chronic graft nephropathy is one of the main causes of 
hypertension after kidney transplantation.[29] Hypertension is quite often the first clinical 
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sign of chronic graft rejection. A great number of authors highlight the association between 
chronic graft nephropathy and hypertension more than the degree of tissue match (HLA), 
suggesting that hypertension is merely one of the causes of chronic graft nephropathy rather 
than its consequence.[8] 
Hypertension is an independent risk factor for the graft dysfunction with the normal 
creatinine level, as well as with the patients that have been previously treated for acute 
rejection. The most frequent consequence of hypertension is hypertrophy of the left 
chamber, angina pectoris, myocardial infarction, stroke, heart weakness, arrhythmia, and 
sudden death.[15] With the appropriate treatment it is possible to induce regression of the 
left ventricle hypertrophy and reduce the risk of cardiovascular diseases. [30] 
3.3. Donor and recipient related factors and the development of hypertension 
Small increases in BP in donors after transplantation do occur and effects are more 
noticeable in donors with lower nephron mass.[31] However, apart from fetal programming, 
nephron mass declines continuously with age and prevalence of nephrosclerosis increases 
linearly and independently from other risk factors from 2.7% for patients aged 18-29 years to 
73% for those aged 70-77 years.[32] Older kidney donors (>55 years) have slightly less than 
half the number of functioning glomeruli compared with younger ones according to a recent 
report.[33] 
Apart from ongoing injury, congenital endowment and donor's age appear to be critical 
determinants of transplant nephron mass. Therefore, it is not surprising that donor age and 
graft size are related to the development of posttransplant hypertension. Recipients of older 
deceased kidney donors are more likely to be hypertensive, whereas patients with low 
kidney transplant to recipient weight ratios are in need of more intense antihypertensive 
regimens.[34, 35] 
Kidney recipients that have received kidney from donors with positive family history for 
hypertension have the higher possibility of developing artery hypertension than the 
recipients who have received the kidney from donors without family history. However, 
patients having primary hypertension as the cause of terminal renal insufficiency, become 
normotensive after bilateral nephrectomy and successful kidney transplantation from 
normotensive donor.[36] 
Recipient’s native kidneys and pre-transplant hypertension are described as independent 
factor associated with post-transplant hypertension. They can cause hypertension in graft 
recipient via renin-angiotensin system.[29] Also, blood pressure in the recipient's transplant 
can be influenced by re-emergence of primary disease, “de novo” glomerulonephritis and 
obstructive uropathy. 
3.4. Posttransplant hypertension due to renal transplant artery stenosis 
Incidence of renal artery stenosis falls within the range of 2-6% and it is comparably much 
lower than 80% incidence of developing post-transplant hypertension.[37] The donors 
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younger than 5 years, termino-terminal anastomosis with internal iliac artery as well as the 
implantation of right kidney are associated with frequent renovascular complications. In a 
retrospective study of 29 recipients with stenosis and a case-control group of 58 patients, an 
increased risk of stenosis was significantly associated with CMV infection and delayed 
function.[38] In contrast to termino-terminal anastomosis with the internal iliac artery, 
termino-terminal anastomosis with the external iliac artery, in children, decreases renal 
artery stenosis incidence. 
Posttransplant hypertension due to renal transplant artery stenosis is important to identify 
because it is a correctable form of hypertension. Although it can present at any time, renal 
artery stenosis usually becomes evident between three months and two years 
posttransplant.[39] 
Clinical suspicion for renal artery stenosis should be raised in situations when audible 
sound can be recorded during the graft auscultation or in the case of abrupt deterioration of 
graft function after administration of angiotensin-converting enzyme inhibitor. 
Hypertension caused by renal artery stenosis is frequently associated with the occurrence of 
diuretic resistant oedema without significant proteinuria, and with the reduced graft 
function. It is often associated with polycythaemia.  
Stenosis can occur on the anastomosis, but also proximal or distal from anastomosis. Typical 
time of occurrence is 6-24 months after transplantation. Factors that can cause the renal 
artery stenosis are: artery injury during explantation and implantation, intimal injury during 
cannulation or weak technique of vascular suture.[40] 
The prevalence of anastomotic renal transplant artery stenosis is difficult to assess. This is 
due in part to discrepancies in the definition of hemodynamically significant lesions and the 
use of different diagnostic modalities. It has been suggested that functionally significant 
stenosis occurs in up to 12 percent of transplant recipients with hypertension, with a range 
of incidence from 1 to 23 percent.[38] 
As with other causes of bilateral renal artery stenosis or unilateral stenosis in a solitary 
kidney, the administration of an angiotensin converting enzyme (ACE) inhibitor or 
angiotensin II receptor blocker (ARB) to a patient with transplant renal artery stenosis can 
lead to a reversible decline in glomerular filtration rate. [39, 41] Thus, an elevation in plasma 
creatinine concentration in this setting is suggestive but not diagnostic of renovascular 
disease in the graft. Persistent uncontrolled hypertension, flash pulmonary edema, and an 
acute elevation in blood pressure are other common features of this disorder.[42] 
Although various different imaging techniques may be utilized to diagnose renal artery 
stenosis, arteriography is the preferred modality. However, since arteriography is invasive, 
magnetic resonance arteriography or CT angiography are increasingly utilized techniques to 
screen and/or diagnose transplant recipients for the presence of renovascular disease.[39, 43] 
The options available to correct stenosis of the renal artery include angioplasty (with or 
without stenting) and surgery. 
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3.5. Consequences of posttransplant hypertension 
Hypertension is one of the main risk factors for cardiovascular diseases and reduction of 
transplant and patient survival. Over the past ten years, the survival of kidney grafts and 
patients have been recording a significant improvement.  
There is little doubt that uncontrolled posttransplant hypertension contributes considerably 
to graft failure and affects patient survival negatively. The Collaborative Transplant Study 
(CTS) group first demonstrated a strong and graded relationship between posttransplant BP 
and renal allograft failure [2], results that have also been validated in subsequent 
studies.[44] Furthermore, persistently poor controlled posttransplant hypertension (defined 
as SBP above 140 mm Hg) was found to be associated with poor outcomes, namely worse 
graft survival and increased cardiovascular mortality.[45] 
The study of 29.000 kidney recipients confirms that the increase of systolic and diastolic 
pressure leads to the higher risk of graft failure. Chronic kidney failure is significantly 
associated with high blood pressure. It is proven that hypertension is an independent risk 
factor in kidney graft failure. It has been reported that in hypertensive recipients with 
systolic blood pressure higher than 150mmHg after the first year from transplantation, there 
is up to 15% better graft survival in four-years period, with prescribed antihypertensive 
therapy. [46] 
4. Treatment of posttransplant hypertension 
4.1. General considerations and pronciples 
The target blood pressure is based in part upon the presence or absence of proteinuria 
and/or additional comorbid conditions, such as diabetes mellitus and/or atherosclerotic 
cardiovascular disease.[1, 5] The K/DOQI guidelines recommend that the target blood 
pressure should be less than 130/80 mmHg.[1] For those with significant proteinuria (greater 
than a spot urine total protein to creatinine ratio of 500 to 1000 mg/g), the K/DOQI work 
group suggests that a lower systolic blood pressure goal should be considered. The 
European best practice guidelines recommend a blood pressure goal of less than 125/75 
mmHg for proteinuric patients. [47] 
The recommended BP targets in renal transplant recipients do not differ from the BP targets 
of nontransplanted patients at high cardiovascular risk, such as diabetic patients and 
patients with CKD or established cardiovascular disease. It is important to note that the 
recommendation to lower systolic BP below 130 mmHg in high-risk hypertensive 
individuals of the (nontransplanted) general population is not even supported by consistent 
trial evidence [48] but also, a series of recent publications report no significant benefit or 
even potential clinical harm by targeting lower BP levels in those patients. 
Posttransplant hypertension should be treated to protect against cardiovascular disease and 
against possible hypertensive injury to the graft. It has been suggested that long-term renal 
allograft survival may be negatively influenced by posttransplant hypertension. [7, 49] 
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There are also clinical data showing benefits with blood pressure control. This was best 
shown in a study of nearly 25,000 first deceased donor kidney recipients.[45] Among 
patients with systolic blood pressures >140 mmHg at one year post-transplant, improved 
long-term allograft outcome was observed among patients with systolic pressures controlled 
to less than 140 mmHg at three years versus those with sustained increases in systolic 
pressure. 
The goal of treatment is to protect graft function and reduce the risk of cardiovascular 
complications. By applying general life style modifications such as weight control, limited 
salt and fat intake, moderate physical activity and smoking cessation it is possible to achieve 
better graft function.[50] 
No antihypertensive drug class is contraindicated in the renal transplant recipient and the 
selection of a specific agent depends mainly on the presence or absence of other 
comorbidities.[1, 51] The reluctance in the use renin-angiotensine-aldosterone system 
(RAAS) blockers and the ability of calcium channel blockers (CCBs) to counteract the 
systemic and renal vasoconstrictive effects of CNIs has influenced the choice of 
antihypertensive therapy.[52] CCBs are currently considered the therapeutic standard for 
the treatment of posttransplant hypertension. A recent meta-analysis of a total of 60 
randomized controlled trials enrolling nearly 4000 kidney transplant recipients showed that 
CCBs were the preferred first-line agents.[53] Yet, in the majority of renal transplant 
recipients, multiple drugs must be given to effectively treat hypertension. As attaining BP 
targets is more important than selection of individual agents, every drug class may be 
appropriate after considering the individual contraindications and the patient's risk 
profile.[54, 55] 
It is necessary to determine the causes of post-transplant hypertension and then establish 
appropriate therapy. Hypertensive patients not taking cyclosporine or tacrolimus should be 
started on antihypertensive medications. Calcium channel blockers, ACE inhibitors, and 
beta-blockers all may be effective in this setting. A diuretic may also be necessary in patients 
with allograft dysfunction in whom volume expansion often contributes to the rise in blood 
pressure. 
In patient on calcineurin inhibitor, an attempt should be made to reduce the calcineurin 
inhibitor dose in hypertensive patients receiving one of these agents. If the patient remains 
hypertensive, therapy with a calcium channel blocker or a diuretic (with concurrent salt 
restriction) should be begun. Other antihypertensive drugs can be added if the blood 
pressure is not controlled with a calcium channel blocker. 
Patients with resistant hypertension should undergo renal arteriography to exclude renal 
artery stenosis unless there are findings (such as renal insufficiency and an active urine 
sediment) suggesting possible recurrence of the primary disease. Angioplasty (with or 
without stenting) or surgery is indicated if a significant stenosis is found. In the absence of 
renovascular disease, recurrent disease, or rejection, consideration should be given to 
removal of the native kidneys if there is no other way to control the hypertension.[56, 57] 
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4.2. Calcium channel blockers 
Many physicians prefer a calcium channel blocker because in addition to proven 
antihypertensive efficacy, it minimizes cyclosporine-induced renal vasoconstriction.[15, 58] 
The influence on renal hemodynamics positively affects the reduction of fluids and also the 
acting of calcineurin inhibitors. Clinical studies show that the usage of calcium antagonists 
with calcineurin inhibitors is connected with the reduction of delayed graft function, with 
lower number of acute rejection episodes and improvement of long-term graft survival.[59]  
A large number of studies have evaluated the efficacy of calcium channel blockers in kidney 
transplant patients. A 2009 systematic review of 29 studies with 2262 patients that compared 
calcium channel blockers to placebo or no treatment as well as seven studies with 405 
patients that compared calcium channel blockers with ACE inhibitors found that calcium 
channel blockers were the most effective antihypertensive agent.[53] This systematic review 
included studies in which patients were not taking a calcineurin inhibitor. 
CCBs and ACE inhibitors equally lower the blood pressure. However, in parallel head-to-
head two year study which compared nifedipine and lisinopril, it was demonstrated that 
calcium antagonists improved renal function in 20% more patients than those taking 
lisinopril.[46] 
Calcium channel blockers may have significant drug interactions with cyclosporine, 
tacrolimus, sirolimus or everolimus (Table 1).[60] Verapamil, diltiazem, nicardipine, and 
amlodipine (to a minor extent), but not nifedipine or isradipine, slow 
cyclosporine/tacrolimus metabolism and elevate the plasma cyclosporine concentration. [60, 
61] Some physicians have recommended the use of nifedipine to prevent this interaction, 
while others prefer verapamil or diltiazem since the inhibition of cyclosporine/tacrolimus 
metabolism permits the use of lower cyclosporine doses. 
4.3. Beta blockers 
Some authors argue that beta blockers should be first line of treatment in patients with 
posttransplant hypertension and co-existing heart disease.[62] Beta blockers may increase 
the triglyceride level, and decrease HDL cholesterol level and in already established 
dislipidemia in immunosupriminary patients may lead to the additional increase in lipid 
levels.[63] Beta blockers also contribute to the development of diabetes.  
Nevertheless, in patients with heart disease and myocardial inarction they should be part of 
usual treatment. Left ventricle hypertrophy is an independent factor of mortality in 60 % of 
the patients with terminal kidney insufficiency while hypertension is a decisive factor in 
hypertrophy pathogenesis of the left chamber. [64] 
4.4. ACE inhibitors and angiotenzin II receptor blockers 
The role of ACE inhibitors/angiotensin II receptor blockers in the transplant patient is 
incompletely defined. These drugs effectively lower the blood pressure and experiments in  
 Current Concepts in Kidney Transplantation 252 
Drug class Indication/benefits Side-effects/contraindications 
a-Blockers Prostate hypertrophy Orthostatic hypotension 
b-Blockers 
Refractory hypertension 
Hyperkalemia 
Chronic graft dysfunction 
Heart failure 
Coronary artery disease 
Atrial fibrillation 
Hypokalemia 
Metabolic syndrome 
Glucose intolerance 
AV-block grade 2 or 3 
Asthma/severe COPD 
Peripheral artery disease 
Calcium 
channel blockers 
Coronary artery disease 
Supraventricular tachycardia  
(non-DHPs) 
Peripheral artery disease 
Edema 
Interactions with CNIs (non-DHPs) 
Proteinuria 
Centrally acting 
agents 
Useful in patients with CKD and 
after kidney transplantation 
(increased sympathetic tone) 
Bradycardia if used with b- blockers 
Diuretics 
Heart failure 
Volume overload 
Gout/hyperuricemia 
Hyponatremia 
RAAS blockers 
Left ventricular hypertrophy 
Systolic heart failure 
Proteinuria 
Hyperkalemia 
Significant transplant artery stenosis 
Pregnancy 
Vasodilators Refractory hypertension 
Orthostatic hypotension 
Fluid sequestration if used without 
diuretics (minoxidil) 
AV-atrioventricular; CKD-chronic kidney disease; CNI-calcineurin inhibitor; COPD-chronic obstructive 
pulmonary disease; DHP-dihydropyridine; GFR-glomerular filtration rate; LVH-left ventricular 
hypertrophy; RAAS-renin–angiotensin–aldosterone system.
Table 1. Potential indications/benefits and side-effect/contraindications of various antihypertensive 
classes in treatment of hypertension after renal transplantation 
animals suggest that they may partially protect against cyclosporine nephrotoxicity when 
compared to similar blood pressure control with hydrochlorothiazide, reserpine, minoxidil, 
hydralazine, or furosemide. [65, 66] 
ACE inhibitors slow down chronic insufficiency of native kidney, and are used for a very 
long time as an alternative in hypertension treatment.[67, 68] The protective functioning 
effects of ACE inhibitor are founded on the decrease of both intraglomerular pressure and 
proteinuria. It is important to point out that angiotensin-converting enzyme inhibitors and 
angiotensin II receptor blockers inhibit the activation of transforming growth factor –β 
(TGF), which is included in pathogenesis of chronic kidney failure. The ability of 
angiotensin-converting enzyme inhibitor to slow down the development of chronic kidney 
failure is proven on animal experiments and it is documented in the recent report.[69] 
However, there are several potential risks with ACE inhibitors/angiotensin II receptor 
blockers in calcineurin-inhibitor treated patients. The combination of ACE inhibition and 
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cyclosporine-induced vascular disease can induce a modest decline in glomerular filtration 
rate via the same mechanism described above for renal artery stenosis [68].[70] Early after 
transplantation (within three to six months post-transplantation), the increase in serum 
creatinine concentration may confound the ability to accurately detect acute rejection. 
Cyclosporine/tacrolimus tends to raise the plasma potassium concentration, primarily by 
decreasing urinary potassium excretion. This effect can be exacerbated by an ACE inhibitor, 
which reduces angiotensin II production and subsequent aldosterone secretion. Thus, ACE 
inhibitors should be avoided in patients who already have a plasma potassium 
concentration above 5.0 meq/L. 
ACE inhibitors can induce anemia in transplant recipients, lowering the hematocrit by as 
much as 5 to 10 percent [69] via an effect that may be enhanced by cyclosporine.[71] Why 
this occurs is incompletely understood but a similar phenomenon probably accounts for the 
efficacy of ACE inhibition in posttransplant erythrocytosis. 
To assess the safety and efficacy of ACE inhibitors and angiotensin II receptor blockers 
(ARBs) in kidney transplant recipients, a large number of retrospective and prospective 
studies have been performed. The magnitude of these effects was evaluated in a 2009 
systematic review of 10 studies with 445 patients that compared angiotensin converting 
enzyme inhibitors to placebo or no treatment and of 7 studies with 405 patients that 
compared angiotensin converting enzyme inhibitors to calcium channel blockers.[53] 
Compared with calcium channel blockers, angiotensin converting enzyme inhibitors were 
associated with a decrease in GFR, proteinuria level, and hemoglobin value and an 
increased incidence of hyperkalemia. 
No definitive conclusions with respect to GFR and allograft loss could be reached when 
angiotensin converting enzyme inhibitors were compared with placebo or no treatment. 
Several retrospective studies in patients with chronic allograft nephropathy have reported 
benefits with these agents in terms of slowing the progression of renal failure and possibly 
mortality.  
4.5. Conclusion 
In conclusion, a great number of patients after renal replacement treatment have poorly 
controlled blood pressure. Numerous studies bring evidence that poorly controlled 
hypertension poses a significant threat to both patient and graft which is why blood 
pressure control may be as equally important as tailoring the individualized 
immunosupressive regime. 
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